Itepekimab
Atopic Dermatitis
Regeneron Pharmaceuticalsmonoclonal_antibodyPhase 2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 27/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Atopic Dermatitis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TACROLIMUS Astellas Pharma China, Inc. | Phase 4 | BB |
pf-04965842 Pfizer | Phase 2 | CCC |
Broncho-Vaxom OM Pharma SA | Phase 2 | CCC |
Dupilumab Sanofi | Phase 2 | CCC |
Same molecule, other indications
Itepekimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →